Zobrazeno 1 - 10
of 266
pro vyhledávání: '"Jonathan L, Curry"'
Autor:
Yi A. Liu, Phyu P. Aung, Yunyi Wang, Jing Ning, Priyadharsini Nagarajan, Jonathan L. Curry, Carlos A. Torres-Cabala, Doina Ivan, Victor G. Prieto, Qingqing Ding, Woo Cheal Cho
Publikováno v:
Journal of Pathology and Translational Medicine, Vol 58, Iss 2, Pp 72-80 (2024)
Background Although trichorhinophalangeal syndrome type 1 (TRPS1) was initially thought to be highly sensitive and specific for carcinomas and mesenchymal tumors of mammary origin, more recent data suggest its expression is not limited to breast neop
Externí odkaz:
https://doaj.org/article/bb45efc5af8244daa9d2f2128ab586c7
Autor:
Justin Qian, BA, Shelby L. Kubicki, MD, Jonathan L. Curry, MD, Richard Jahan-Tigh, MD, Robert Benjamin, MD, Meghan Heberton, MD, Kelly C. Nelson, MD
Publikováno v:
JAAD Case Reports, Vol 29, Iss , Pp 21-24 (2022)
Externí odkaz:
https://doaj.org/article/210b59fa1da349d08dedf8975d1a8465
Autor:
Mario L. Marques-Piubelli, Jesus Navarrete, Debora A. Ledesma, Courtney W. Hudgens, Rossana N. Lazcano, Ali Alani, Auris Huen, Madeleine Duvic, Priyadharsini Nagarajan, Phyu P. Aung, Ignacio I. Wistuba, Jonathan L. Curry, Roberto N. Miranda, Carlos A. Torres-Cabala
Publikováno v:
Cells, Vol 13, Iss 5, p 419 (2024)
Granulomatous Mycosis Fungoides (GMF) is a rare form of mycosis fungoides (MF) characterized by a granulomatous infiltrate associated with the neoplastic lymphoid population and is considered to have a worse prognosis compared with regular MF. The up
Externí odkaz:
https://doaj.org/article/d32a078379274fe698707b1ef99c729c
Autor:
Christopher N. Nguyen, BA, Swaminathan P. Iyer, MD, Roberto N. Miranda, MD, Carlos A. Torres-Cabala, MD, Jonathan L. Curry, MD, Penny Fang, MD, Valencia D. Thomas, MD, Auris O. Huen, MD
Publikováno v:
JAAD Case Reports, Vol 17, Iss , Pp 34-37 (2021)
Externí odkaz:
https://doaj.org/article/29f780d90c1a4722916fc4eea6d73f95
Autor:
Padmavathi Karri, BS, Benjamin Freemyer, MD, Nader Aboul-Fettouh, MD, Anisha B. Patel, MD, Jonathan L. Curry, MD, Megan Rogge, MD
Publikováno v:
JAAD Case Reports, Vol 7, Iss , Pp 26-29 (2021)
Externí odkaz:
https://doaj.org/article/20e939c529794852bcc2af7c5ff1f512
Autor:
Claire J. Wiggins, BS, Van K. Morris, MD, Natasha K. Klimas, MD, Priyadharsini Nagarajan, MD, PhD, Jonathan L. Curry, MD, Kristen N. Richards, MD
Publikováno v:
JAAD Case Reports, Vol 13, Iss , Pp 23-25 (2021)
Externí odkaz:
https://doaj.org/article/f7ecba4e81454118b18b0f9529682988
Autor:
Kevin E. Fisher, Lizmery S. Ferguson, Amy M. Coffey, Brian Y. Merritt, Jonathan L. Curry, Andrea N. Marcogliese, Angela M. Major, Kala Y. Kamdar, Dolores H. Lopez-Terrada, Choladda V. Curry
Publikováno v:
Haematologica, Vol 107, Iss 8 (2022)
Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are immunomodulatory molecules overexpressed in lymphomas and are promising immunotherapy targets for hematologic malignancies. However, studies of PD-1/PD-L1 overexpression an
Externí odkaz:
https://doaj.org/article/4acae81cae8a448f82cf0d0b57fc9a8d
Autor:
Michelle A. McNally, BSN, Ramya Vangipuram, MD, Matthew T. Campbell, MD, Priyadharsini Nagarajan, MD, PhD, Anisha B. Patel, MD, Jonathan L. Curry, MD, Meghan Heberton, MD
Publikováno v:
JAAD Case Reports, Vol 10, Iss , Pp 82-84 (2021)
Externí odkaz:
https://doaj.org/article/f296043fa8734222ac3cfd5179a26046
Autor:
Woo Cheal Cho, Qingqing Ding, Wei‐Lien Wang, Priyadharsini Nagarajan, Jonathan L. Curry, Carlos A. Torres‐Cabala, Doina Ivan, Constance T. Albarracin, Aysegul Sahin, Victor G. Prieto, Phyu P. Aung
Publikováno v:
Journal of Cutaneous Pathology. 50:434-440
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4218804b3035aebd48540e553b0fb035
https://doi.org/10.1111/cup.14414
https://doi.org/10.1111/cup.14414
Autor:
Paul V. Viscuse, Mario L. Marques-Piubelli, Meghan M. Heberton, Edwin Roger Parra, Amishi Y. Shah, Arlene Siefker-Radtke, Jianjun Gao, Sangeeta Goswami, Doina Ivan, Jonathan L. Curry, Matthew T. Campbell
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from N
Externí odkaz:
https://doaj.org/article/55a10ccbe61c41a892852b9f573c314e